Chordia Therapeutics,Inc Logo

Chordia Therapeutics,Inc

Developing first-in-class, small-molecule anti-cancer drugs targeting RNA deregulation.

190A | T

Overview

Corporate Details

ISIN(s):
JP3283730004
LEI:
Country:
Japan
Address:
藤沢市村岡東2−26−1
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Chordia Therapeutics Inc. is a clinical-stage biotechnology company specializing in the research and development of innovative, first-in-class anti-cancer drugs. Established in November 2017 as a spin-out from a major pharmaceutical company, its mission is to deliver novel treatments to patients with unmet medical needs. The company focuses on developing a pipeline of small-molecule drug candidates that target RNA deregulation stress, a key factor in cancer development. Chordia Therapeutics operates with a focused R&D model, outsourcing activities such as manufacturing, distribution, and sales to external partners to advance its therapeutic programs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-21 05:00
Registration Form
確認書
Japanese 8.1 KB
2025-11-21 05:00
Annual Report
有価証券報告書-第8期(2024/09/01-2025/08/31)
Japanese 2.6 MB
2025-09-05 08:30
Registration Form
有価証券届出書(参照方式)
Japanese 534.8 KB
2025-05-16 02:45
Major Shareholding Notification
臨時報告書
Japanese 20.2 KB
2025-04-11 04:50
Interim Report
半期報告書-第8期(2024/09/01-2025/08/31)
Japanese 144.4 KB
2025-04-11 04:50
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-12-17 07:30
Registration Form
訂正確認書
Japanese 8.7 KB
2024-11-29 07:37
Post-Annual General Meeting Information
臨時報告書
Japanese 23.1 KB
2024-11-29 07:36
Registration Form
確認書
Japanese 8.1 KB
2024-11-29 07:35
Governance Information
内部統制報告書-第7期(2023/09/01-2024/08/31)
Japanese 21.2 KB
2024-11-29 07:34
Annual Report
有価証券報告書-第7期(2023/09/01-2024/08/31)
Japanese 2.8 MB
2024-07-16 06:55
Quarterly Report
四半期報告書-第7期第3四半期(2024/03/01-2024/05/31)
Japanese 123.4 KB
2024-07-16 06:55
Report Publication Announcement
確認書
Japanese 8.0 KB
2024-06-06 08:00
Registration Form
訂正有価証券届出書(新規公開時)
Japanese 2.9 MB
2024-05-29 04:00
Registration Form
訂正有価証券届出書(新規公開時)
Japanese 2.9 MB

Automate Your Workflow. Get a real-time feed of all Chordia Therapeutics,Inc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Chordia Therapeutics,Inc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Chordia Therapeutics,Inc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

MicroAd,Inc. Logo
Data-driven marketing tech providing DSP and SSP solutions for digital advertising.
Japan
9553
Microwave Chemical Co., Ltd. Logo
Innovating chemical and metal processing with an eco-friendly microwave platform.
Japan
9227
MindWalk Holdings Corp. Logo
AI-powered biotherapeutics firm offering end-to-end antibody discovery and engineering services.
United States of America
HYFT
Minerva Neurosciences, Inc. Logo
A clinical-stage biopharma developing treatments for central nervous system (CNS) diseases.
United States of America
NERV
A think tank providing research, consulting, and ICT solutions to public & private sectors.
Japan
3636
Modalis Therapeutics Corporation Logo
Develops epigenome editing therapies for genetic muscular, heart, and CNS disorders.
Japan
4883
Model Solution Co., Ltd. Logo
One-stop prototyping & low-volume production for IT, electronics, and medical hardware.
South Korea
417970
Modus Therapeutics Holding AB Logo
Developing sevuparin, a polysaccharide for sepsis, septic shock, and chronic inflammation.
Sweden
MODTX
Moleculin Biotech, Inc. Logo
Developing therapies for hard-to-treat tumors (like AML) and viruses.
United States of America
MBRX
Molecure S.A. Logo
Develops first-in-class small molecule drugs for oncology and inflammatory/fibrotic diseases.
Poland
MOC

Talk to a Data Expert

Have a question? We'll get back to you promptly.